Trials / Active Not Recruiting
Active Not RecruitingNCT06395753
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Advanced Prostate Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Debiopharm International SA · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Debio 4228 | Administered as IM injection. |
Timeline
- Start date
- 2024-05-23
- Primary completion
- 2026-12-01
- Completion
- 2027-01-01
- First posted
- 2024-05-02
- Last updated
- 2026-03-30
Locations
33 sites across 4 countries: United States, Belgium, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06395753. Inclusion in this directory is not an endorsement.